1574 Journal of Medicinal Chemistry, 2005, Vol. 48, No. 5
Ulmschneider et al.
(23) Rabjohn, M. 2,3-Dimethoxycinnamic acid. Org. Synth. Collect.
1963, 327-329.
References
(1) Kawamoto, T.; Mitsuuchi, Y.; Toda, K.; Yokoyama, Y.; Miyahara,
K.; Miura, S.; Ohnishi, T.; Ichikawa, Y.; Nakao, K.; Imura, H.
Role of steroid 11 beta-hydroxylase and steroid 18-hydroxylase
in the biosynthesis of glucocorticoids and mineralocorticoids in
humans. Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 1458-1462.
(2) Brilla, C. G. Renin-angiotensin-aldosterone system and myo-
cardial fibrosis. Cardiovasc. Res. 2000, 47, 1-3.
(3) Pitt, B.; Remme, W.; Zannad, F.; Neaton, J.; Martinez, F.;
Roniker, B.; Bittman, R.; Hurley, S.; Kleiman, J.; Gatlin, M.
Eplerenone, a selective aldosterone blocker, in patients with left
ventricular dysfunction after myocardial infarction. N. Engl. J.
Med. 2003, 348, 1309-1321.
(4) Pitt, B.; Zannad, F.; Remme, W. J.; Cody, R.; Castaigne, A.;
Perez, A.; Palensky, J.; Wittes, J. The effect of spironolactone
on morbidity and mortality in patients with severe heart failure.
Randomized Aldactone Evaluation Study Investigators. N. Engl.
J. Med. 1999, 341, 709-717.
(5) Christ, M.; Grimm, W.; Maisch, B. Significance of aldosterone
antagonist therapy. Internist (Berlin) 2004, 45, 347-354.
(6) Delyani, J. A. Mineralocorticoid receptor antagonists: The
evolution of utility and pharmacology. Kidney Int. 2000, 57,
1408-1411.
(7) Ehmer, P. B.; Bureik, M.; Bernhardt, R.; Mu¨ller, U.; Hartmann,
R. W. Development of a test system for inhibitors of human
aldosterone synthase (CYP11B2): Screening in fission yeast and
evaluation of selectivity in V79 cells. J. Steroid Biochem. Mol.
Biol. 2002, 81, 173-179.
(8) Hartmann, R. W.; Mu¨ller, U.; Ehmer, P. B. Discovery of selective
CYP11B2 (aldosterone synthase) inhibitors for the therapy of
congestive heart failure and myocardial fibrosis. Eur. J. Med.
Chem. 2003, 38, 363-366.
(24) Musso, D. L.; Cochran, F. R.; Kelley, J. L.; McLean, E. W.; Selph,
J. L.; Rigdon, G. C.; Orr, G. F.; Davis, R. G.; Cooper, B. R.; Styles,
V. L.; Thompson, J. B.; Hall, W. R. Indanylidenes. 1. Design and
synthesis of (E)-2-(4,6-difluoro-1-indanylidene)acetamide, a po-
tent, centrally acting muscle relaxant with antiinflammatory and
analgesic activity. J. Med. Chem. 2003, 46, 399-408.
(25) Dondoni, A.; Fantin, G.; Fogagnolo, M.; Medici, A.; Pedrini, P.
A new convenient preparation of 2-, 4-, and 5-thiazolecarboxal-
dehydes and their conversion into the corresponding carbonitrile
N-oxides: Synthesis of 3-thiazolyl-isoxazoles and 3-thiazolyl-
isoxazolines. Synthesis 1987, 11, 998-1001.
(26) Rho, T.; Abuh, Y. F. One pot synthesis of pyrimidine-5-carbox-
aldehyde and ethyl pyrimidine-5-carboxylate by utilizing pyri-
midin-5-yl-lithium. Synth. Commun. 1994, 24, 253-256.
(27) Denner, K.; Doehmer, J.; Bernhardt, R. Cloning of CYP11B1 and
CYP11B2 from normal human adrenal and their functional
expression in COS-7 and V79 chinese hamster cells. Endocr. Res.
1995, 21, 443-448.
(28) Denner, K.; Vogel, R.; Schmalix, W.; Doehmer, J.; Bernhardt,
R. Cloning and stable expression of the human mitochondrial
cytochrome P45011B1 cDNA in V79 chinese hamster cells and
their application for testing of potential inhibitors. Pharmaco-
genetics 1995, 5, 89-96.
(29) Thompson, E. A., Jr.; Siiteri, P. K. Utilization of oxygen and
reduced nicotinamide adenine dinucleotide phosphate by human
placental microsomes during aromatization of androstenedione.
J. Biol. Chem. 1974, 249, 5364-5372.
(30) Hartmann, R. W.; Batzl, C. Aromatase inhibitors. Synthesis and
evaluation of mammary tumor inhibiting activity of 3-alkylated
3-(4-aminophenyl)piperidine-2,6-diones. J. Med. Chem. 1986, 29,
1362-1369.
(31) Hutschenreuter, T. U.; Ehmer, P. B.; Hartmann, R. W. Synthesis
of hydroxy derivatives of highly potent nonsteroidal CYP17
inhibitors as potential metabolites and evaluation of their
activity by a non cellular assay using recombinant enzyme. J.
Enzyme Inhib. Med. Chem. 2004, 19, 17-32.
(32) Williams, P. A.; Cosme, J.; Ward, A.; Angove, H. C.; Matak
Vinkovic, D.; Jhoti, H. Crystal structure of human cytochrome
P4502C9 with bound warfarin. Nature 2003, 424, 464-468.
(33) Bo¨ttner, B.; Bernhardt, R. Changed ratios of glucocorticoids/
mineralocorticoids caused by point mutations in the putative
I-helix regions of CYP11B1 and CYP11B2. Endocr. Res. 1996,
22, 455-461.
(34) Bo¨ttner, B.; Schrauber, H.; Bernhardt, R. Engineering a min-
eralocorticoid- to a glucocorticoid-synthesizing cytochrome P450.
J. Biol. Chem. 1996, 271, 8028-8033.
(35) Ha¨usler, A.; Monnet, G.; Borer, C.; Bhatnagar, A. S. Evidence
that corticosterone is not an obligatory intermediate in aldo-
sterone biosynthesis in the rat adrenal. J. Steroid Biochem.
1989, 34, 567-570.
(36) Bhatnagar, A. S.; Ha¨usler, A.; Schieweck, K.; Lang, M.; Bowman,
R. Highly selective inhibition of estrogen biosynthesis by CGS
20267, a new nonsteroidal aromatase inhibitor. J. Steroid
Biochem. Mol. Biol. 1990, 37, 1021-1027.
(37) De Coster, R.; Caers, I.; Coene, M. C.; Amery, W.; Beerens, D.;
Haelterman, C. Effects of high dose ketoconazole therapy on the
main plasma testicular and adrenal steroids in previously
untreated prostatic cancer patients. Clin. Endocrinol. (Oxford)
1986, 24, 657-664.
(38) Albrecht, R.; Schro¨der, E. Chemotherapeutic nitro-heterocyclic
compounds. 3. Preparation of nitrofurfurylidene-, nitrothie-
nylidene- and nitropyrrolylmethylene-derivatives of substitued
1-indanones and 1.2.3.4-tetrahydro-1-naphthalenones. Justus
Liebigs Ann. Chem. 1970, 736, 110-125.
(39) Horwell, D. C.; Howson, W.; Nolan, W. P.; S., R. G.; Rees, D. C.;
Willems, H. M. G. The design of dipeptidic helical mimetics, part
I: The synthesis of 1,6-disubstituted indanes. Tetrahedron 1995,
51, 203-216.
(9) Baumann, C. K.; Aebi, S. Aromatase inhibitors in the adjuvant
therapy of breast carcinomas. Ther. Umsch. 2004, 61, 359-364.
(10) Pilon, C.; Mulatero, P.; Barzon, L.; Veglio, F.; Garrone, C.;
Boscaro, M.; Sonino, N.; Fallo, F. Mutations in CYP11B1 gene
converting 11beta-hydroxylase into an aldosterone-producing
enzyme are not present in aldosterone-producing adenomas. J.
Clin. Endocrinol. Metab. 1999, 84, 4228-4231.
(11) Wisconsin Package Version 10.1, Genetics Computer Group
(GCG), Madison, WI.
(12) Ulmschneider, S.; Mu¨ller-Vieira, U.; Mitrenga, M.; Hartmann,
R. W.; Oberwinkler-Marchais, S.; Klein, C. D.; Bureik, M.;
Bernhardt, R.; Antes, I.; Lengauer, T. Synthesis and evaluation
of imidazolylmethylene-tetrahydronaphthalenes and imidazolyl-
methylene-indanes: Potent inhibitors of aldosterone synthase.
10.1021/jm049600p).
(13) Dowsett, M.; Stein, R. C.; Mehta, A.; Coombes, R. C. Potency
and selectivity of the nonsteroidal aromatase inhibitor CGS
16949A in postmenopausal breast cancer patients. Clin. Endo-
crinol. (Oxford) 1990, 32, 623-634.
(14) Demers, L. M.; Melby, J. C.; Wilson, T. E.; Lipton, A.; Harvey,
H. A.; Santen, R. J. The effects of CGS 16949A, an aromatase
inhibitor on adrenal mineralocorticoid biosynthesis. J. Clin.
Endocrinol. Metab. 1990, 70, 1162-1166.
(15) Bureik, M.; Hubel, K.; Dragan, C. A.; Scher, J.; Becker, H.; Lenz,
N.; Bernhardt, R. Development of test systems for the discovery
of selective human aldosterone synthase (CYP11B2) and 11beta-
hydroxylase (CYP11B1) inhibitors. Discovery of a new lead
compound for the therapy of congestive heart failure, myocardial
fibrosis and hypertension. Mol. Cell. Endocrinol. 2004, 217, 249-
254.
(16) Hartmann, R. W. Selective inhibition of steroidogenic P450
enzymes: Current status and future perspectives. Eur. J.
Pharm. Sci. 2 1994, 15-16.
(17) Van Wauwe, J. P.; Janssen, P. A. Is there a case for P-450
inhibitors in cancer treatment? J. Med. Chem. 1989, 32, 2231-
2239.
(18) El Ahmad, Y.; Laurent, E.; Maillet, P.; Talab, A.; Teste, J. F.;
Dokhan, R.; Tran, G.; Ollivier, R. New benzocycloalkylpipera-
zines, potent and selective 5-HT1A receptor ligands. J. Med.
Chem. 1997, 40, 952-960.
(19) Hercouet, A.; Le Corre, M. Triphenylphosphonium bromide: A
convenient and quantitative source of gaseous hydrogen bromide.
Synth. Commun. 1988, 157-158.
(20) Reimann, E.; Hargasser, E. Synthese von cis-9,11a-dimethyl-
4,5,6,6a,7a,8,9,10,11,11a-decahydro-7H-naphtho(1,8-fg)isochino-
linen (Synthesis of cis-9,11a-dimethyl-4,5,6,6a,7a,8,9,10,11,11a-
decahydro-7H-naphtho(1,8-fg)isoquinolines). Arch. Pharm. 1989,
327, 159-164.
(40) Takeuchi, R.; Yasue, H. Rhodium complex-catalyzed desilylative
cyclocarbonylation of 1-aryl-2-(trimethylsilyl)acetylenes: A new
route to 2,3-dihydro-1H-inden-1-ones. J. Org. Chem. 1993, 58,
5386-5392.
(41) Luo, J.-K.; Castle, S. L.; Castle, R. N. The synthesis of difluoro-
1
benzothieno<2,3-c>quinolines and their N-methyl quater-
nary salts. J. Heterocycl. Chem. 1990, 27, 2047-2052.
(42) Yuzikhin, O. S.; Vasil’ev, A. V.; Rudenko, A. P. Oxidation of
aromatic compounds: VIII. Oxidative dehydrodimerization of
cinnamic acid derivatives in the system CF3COOH-CH2Cl2-
PbO2. Russ. J. Org. Chem. 2000, 36, 1743-1754.
(21) Donbrow, M. Cyclisation and debenzylation of m-benzyloxypro-
pionic acid as competitive reactions. J. Chem. Soc. 1959, 1613-
1615.
(22) Budhram, R. S.; Palaniswamy, V. A.; Eisenbraun, E. J. Steric
effects in the synthesis of 1,7-dialkylindanes. J. Org. Chem.
1986, 51, 1402-1406.
(43) Olivier, M.; Marechal, E. Etude de monomeres halogenes et de
leur polymerisation cationique. I.- Synthese de divers fluoro-
indenes (Study on halogenated monomers and their cationic
polymerisation. Synthesis of several fluoro-indenes). Bull. Soc.
Chim. Fr. 1973, 3092-3095.